Phase 2A study of the phosphatidylinositol-3-kinase (Pi3K) inhibitor copanlisib in patients with relapsed/refractory, indolent or aggressive lymphoma
Authors
Dreyling, MMorschhauser, F
Bouabdallah, K
Cunningham, D
Bron, D
Linton, Kim M
Assouline, S
Verhoef, G
Thieblemont, C
Vitolo, U
Garcia-Vargas, J
Gorbatchevsky, I
Neves, M
Grunert, J
Hiemeyer, F
Childs, B
Zinzani, P
Affiliation
Klinikum der Universitat Munchen, MunichIssue Date
2016